Psoriasis

Fortnightly secukinumab better for heavier psoriasis patients

Risankizumab can be used in patients with Crohn’s

Impact of dermatological disease is more than skin deep

Rituximab and non-white ethnicity linked with worse covid outcomes

MS linked to psoriasis risk in family members

Biologics improve psoriasis but not CV risk

Psoriasis drug passes another milestone

Promising findings for PsA treatments
